AMRN Amarin Corporation plc - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AMRN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - General
Current Price
Live
$15.34
Analyst Target
$12.0
-21.8%
Downside
52W High
$20.9
52W Low
$7.6
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
AMRN's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining revenue, and negative earnings trends. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given the company's negative ROE, ROA, and persistent losses despite a strong gross margin. While the company exhibits a low debt-to-equity ratio and high liquidity, these strengths are overshadowed by a 21% YoY revenue decline and a 94.7% Q/Q EPS drop. Analysts have issued a 'underperform' rating with a target price below current levels, reflecting skepticism about near-term sustainability. The stock's recent 87% 1-year gain is likely driven by speculative momentum rather than fundamentals.
Key Strengths
High gross margin of 56.57% suggests strong pricing power or cost control in production
Extremely low debt-to-equity ratio of 0.02 indicates minimal financial leverage and low default risk
Strong liquidity with current ratio of 3.34 and quick ratio of 2.21, providing buffer against short-term obligations
Recent positive earnings surprises in prior quarters (e.g., +242.6% in 2025-07-30) indicate potential for earnings recovery
Significant 1-year price appreciation (+87.1%) suggests strong market sentiment and potential for short-term momentum
Key Risks
Piotroski F-Score of 2/9 signals severe financial weakness, with multiple red flags including negative ROE, ROA, and declining profitability
21% year-over-year revenue decline and negative earnings growth indicate deteriorating business fundamentals
No analyst consensus on forward earnings, with target price of $12.00 below current price, signaling bearish outlook
Absence of a Graham Number and Intrinsic Value suggests no reliable valuation anchor, increasing speculative risk
Insider trading activity is neutral with zero buy/sell transactions in the last 6 months, indicating lack of confidence or interest
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare AMRN against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning AMRN from our newsroom.
Newest → oldest
No matching news yet.